Search…

Lates News

20/04/2026

Novo Nordisk (NVO.N): Etavopivat achieved two co-primary endpoints in the Phase III HIBISCUS trial for sickle cell disease. In the Phase III trial, etavopivat reduced vascular occlusion crisis events by 27%. Regulatory approval application for etavopivat is planned to be submitted for the first time in the second half of 2026.

Latest

2 m ago

The former chairman of Chongqing Commercial Investment Group Co., Ltd., Fan Guangming, is under investigation.

2 m ago

Shanghai: Building Shanghai into the preferred destination for overseas entrepreneurial teams to develop in China.

3 m ago

Brady: Acquiring Honeywell's productivity solutions and services business. The transaction is a $1.4 billion all-cash deal. It is expected that this transaction will immediately have a double-digit accretive effect on adjusted earnings per share. The transaction will be funded through existing cash and additional debt financing.

3 m ago

On April 20, the Kazakhstan financial technology company Kaspi.kz announced that Tencent, along with the company's management and long-term investors, had completed the acquisition of 6 million American Depositary Shares from the Warburg Pincus FinTech Venture Fund. Kaspi stated that in addition to Tencent, other buyers included financial technology investment company Spice Expeditions, as well as American university endowment funds such as the University of Washington and the University of Wisconsin Foundation. (Jiemian).

3 m ago

Brady: Will acquire Honeywell's productivity solutions and services business. The transaction is a $1.4 billion all-cash deal. It is expected that the transaction will immediately have a double-digit accretive effect on adjusted earnings per share. The transaction will be funded through existing cash and additional debt financing.

See all latest